Amgen to push latecomer obesity drug into midstage testing

Amgen is lagging behind rivals like Novo Nordisk and Eli Lilly with its new-generation therapy for obesity, but is sufficiently encouraged by early-stage clinical data to kick off a phase 2

Merck & Co to repurpose failed obesity drug for NASH

Merck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson & Johnson, into a therapy for the fatty liver disease known as NASH.

MiNA’s gene-activating tech wins an AstraZeneca alliance

Novo’s new oral GLP-1 Rybelsus still has obstacles to overco...

Vertex looks beyond cystic fibrosis with $950m Semma buy

Pfizer, Novo invest in Swedish patient stratification startu...

Funds will go towards development of AMRA's body composition profiling tool AMRA Profiler.